Document Detail

Levosimendan in acute heart failure following primary percutaneous coronary intervention-treated acute ST-elevation myocardial infarction. Results from the LEAF trial: a randomized, placebo-controlled study.
MedLine Citation:
PMID:  23288914     Owner:  NLM     Status:  Publisher    
AIMS: The calcium sensitizer levosimendan may counteract stunning after reperfusion of ischaemic myocardium, but no randomized placebo-controlled trials exist regarding its use in PCI-treated ST-segment elevation infarction (STEMI). We evaluated the efficacy and safety of levosimendan in patients with a primary PCI-treated STEMI complicated by symptomatic heart failure (HF). METHODS AND RESULTS: A total of 61 patients developing clinical signs of HF within 48 h after a primary PCI-treated STEMI (including cardiogenic shock) were randomized double-blind to a 25 h infusion of levosimendan or placebo. The primary endpoint was change in wall motion score index (WMSI) from baseline to day 5 measured by echocardiography. There was a significantly larger improvement in WMSI from baseline to day 5 in the levosimendan group compared with placebo (from 1.94 ± 0.20 to 1.66 ± 0.31 vs. 1.99 ± 0.22 to 1.83 ± 0.26, respectively, P = 0.031). There were significantly more episodes of hypotension during study drug infusion in the levosimendan group (67% vs. 36%, P = 0.029), but no significant difference in blood pressure at the end of infusion or in use of vasopressors. No significant between-group differences in changes in NT-proBNP levels, clinical composite score, frequency of atrial fibrillation or ventricular arrhythmia, infarct size at 6 weeks, or new clinical events up to 6 months were found. One and four patients died in the levosimendan and placebo group, respectively. CONCLUSIONS: Levosimendan treatment improved contractility in post-ischaemic myocardium in patients with PCI-treated STEMI complicated by HF. The treatment was well tolerated, without any increase in arrhythmias.Trial registration: NCT00324766.
Trygve Husebye; Jan Eritsland; Carl Müller; Leiv Sandvik; Harald Arnesen; Ingebjørg Seljeflot; Arild Mangschau; Reidar Bjørnerheim; Geir Øystein Andersen
Related Documents :
23759284 - Lenient vs. strict rate control in patients with atrial fibrillation and heart failure:...
2639914 - Hypo-hyperdontia in an irish population.
23839654 - Myocardial perfusion reserve is impaired in patients with chronic obstructive pulmonary...
23265334 - Quality of life and functional capacity in patients with atrial fibrillation and conges...
16077384 - Ginsenosides compound (shen-fu) attenuates gastrointestinal injury and inhibits inflamm...
16327954 - Left atrial myxoma presenting with acute myocardial infarction--a case report.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-1-2
Journal Detail:
Title:  European journal of heart failure     Volume:  -     ISSN:  1879-0844     ISO Abbreviation:  Eur. J. Heart Fail.     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-1-4     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100887595     Medline TA:  Eur J Heart Fail     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Department of Cardiology, Oslo University Hospital Ullevål, Norway.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Determinants of dynamic changes in serum creatinine in acute decompensated heart failure: the import...
Next Document:  Chloroquine in cancer therapy: a double-edged sword of autophagy.